{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:43:04Z","timestamp":1780418584505,"version":"3.54.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01708"],"award-info":[{"award-number":["PI21\/01708"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The COVID-19 pandemic highlighted the importance of effective vaccination strategies in controlling the spread of infectious diseases. SARS-CoV-2 vaccine has demonstrated high efficacy in preventing COVID-19 infection in the general population. However, the efficacy of this vaccine in patients with predominantly antibody deficiencies, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), should be closely monitored. CVID and XLA are rare genetic disorders that impair the immune system\u2019s ability to produce antibodies, which are crucial for fighting infections. Patients with these disorders have a higher risk of severe disease and mortality from COVID-19 due to their compromised immune systems. In this study, we evaluated the humoral and cellular immune responses after four doses of mRNA-1273 and one BNT162b2 bivalent vaccine in a cohort of patients with CVID and XLA. The response in this population was lower than in the control group. However, the administration of the third dose improved the number of patients with seroconversion and the intensity of the humoral response, as well as the number of patients with a positive cellular response. Finally, the administration of the fourth and fifth doses improves the antibody titer and neutralization against wild type variant, but not against the prevalent XBB1.5 variant.<\/jats:p>","DOI":"10.1093\/cei\/uxae039","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T06:41:30Z","timestamp":1714632090000},"page":"253-262","source":"Crossref","is-referenced-by-count":7,"title":["Follow-up of immune response in patients with common variable immunodeficiency following SARS-CoV-2 vaccination"],"prefix":"10.1093","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-0756","authenticated-orcid":false,"given":"Juan Francisco","family":"Guti\u00e9rrez-Bautista","sequence":"first","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Biolog\u00eda Molecular e Inmunolog\u00eda III, University of Granada , Granada , Spain"},{"name":"Servicio de An\u00e1lisis Cl\u00ednicos e Inmunolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA) , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"D\u00edaz-Alberola","sequence":"additional","affiliation":[{"name":"Servicio de An\u00e1lisis Cl\u00ednicos e Inmunolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA) , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Tarri\u00f1o","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Aguilera","sequence":"additional","affiliation":[{"name":"Servicio de Microbiolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cobo","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA) , Granada , Spain"},{"name":"Servicio de Microbiolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Reguera","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA) , Granada , Spain"},{"name":"Servicio de Microbiolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodr\u00edguez-Granger","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA) , Granada , Spain"},{"name":"Servicio de Microbiolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Vircell S.L. , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"L\u00f3pez-Nevot","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica, Biolog\u00eda Molecular e Inmunolog\u00eda III, University of Granada , Granada , Spain"},{"name":"Servicio de An\u00e1lisis Cl\u00ednicos e Inmunolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"},{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA) , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sampedro","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibs.GRANADA) , Granada , Spain"},{"name":"Servicio de Microbiolog\u00eda, University Hospital Virgen de las Nieves , Granada , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2024080909361052900_CIT0001","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"2024080909361052900_CIT0002","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.autrev.2018.05.001","article-title":"Monogenic polyautoimmunity in primary immunodeficiency diseases","volume":"17","author":"Azizi","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2024080909361052900_CIT0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaut.2019.01.011","article-title":"Primary immunodeficiency and autoimmunity: a comprehensive review","volume":"99","author":"Amaya-Uribe","year":"2019","journal-title":"J Autoimmun"},{"key":"2024080909361052900_CIT0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.18176\/jiaci.0388","article-title":"Common variable immunodeficiency: epidemiology, pathogenesis, clinical manifestations, diagnosis, classification, and management","volume":"30","author":"Yazdani","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2024080909361052900_CIT0005","first-page":"42","article-title":"(2022) \u201cCommon variable immunodeficiency: challenges for diagnosis\u201d","volume":"509","author":"Wang","year":"1133","journal-title":"J Immunol Methods"},{"key":"2024080909361052900_CIT0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12016-021-08870-5","article-title":"Agammaglobulinemia: from X-linked to autosomal forms of disease","volume":"63","author":"Cardenas-Morales","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"2024080909361052900_CIT0007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024080909361052900_CIT0008","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","article-title":"COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience","volume":"147","author":"Shields","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024080909361052900_CIT0009","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41586-023-06717-x","article-title":"Autoantibodies against type I IFNs in humans with alternative NF-\u03baB pathway deficiency","volume":"623","author":"Le Voyer","year":"2023","journal-title":"Nature"},{"key":"2024080909361052900_CIT0010","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jaci.2022.04.002","article-title":"Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity","volume":"149","author":"van Leeuwen","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2024080909361052900_CIT0011","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2024080909361052900_CIT0012","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.jaip.2020.04.019","article-title":"Preserved cellular immunity upon influenza vaccination in most patients with common variable immunodeficiency","volume":"8","author":"Friedmann","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024080909361052900_CIT0013","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024080909361052900_CIT0014","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2021.12.011","article-title":"Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article","volume":"162","author":"Barri\u00e8re","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024080909361052900_CIT0015","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/annrheumdis-2022-222498","article-title":"Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE)","volume":"81","author":"Mageau","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024080909361052900_CIT0016","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/hmg\/ddac132","article-title":"Novel genes and sex differences in COVID-19 severity","volume":"31","author":"Cruz","year":"2022","journal-title":"Hum Mol Genet"},{"key":"2024080909361052900_CIT0017","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1159\/000526375","article-title":"Immunogenicity and Safety of the Spikevax\u00ae (Moderna) mRNA SARS-CoV-2 vaccine in patients with primary humoral immunodeficiency","volume":"183","author":"Kralickova","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"2024080909361052900_CIT0018","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jaci.2021.11.022","article-title":"Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects","volume":"149","author":"Pham","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2024080909361052900_CIT0019","doi-asserted-by":"crossref","first-page":"727850","DOI":"10.3389\/fimmu.2021.727850","article-title":"Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies","volume":"12","author":"Amodio","year":"2021","journal-title":"Front Immunol"},{"key":"2024080909361052900_CIT0020","doi-asserted-by":"crossref","first-page":"907125","DOI":"10.3389\/fimmu.2022.907125","article-title":"Specific antibody and the T-cell response elicited by BNT162b2 boosting after two ChAdOx1 nCoV-19 in common variable immunodeficiency","volume":"13","author":"Goda","year":"2022","journal-title":"Front Immunol"},{"key":"2024080909361052900_CIT0021","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cei\/uxac001","article-title":"T-cell responses to SARS-CoV-2 in healthy controls and primary immunodeficiency patients","volume":"207","author":"Awuah","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2024080909361052900_CIT0022","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/apm.13215","article-title":"Study of humoral and cellular immunity in vaccinated with mRNA-1273","volume":"130","author":"Guti\u00e9rrez-Bautista","year":"2022","journal-title":"APMIS"},{"key":"2024080909361052900_CIT0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-0795-4_1","article-title":"Vaccine delivery and immune response basics","volume":"2183","author":"Hill","year":"2021","journal-title":"Methods Mol Biol"},{"key":"2024080909361052900_CIT0024","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s10875-021-01133-0","article-title":"SARS-CoV-2 vaccine induced atypical immune responses in antibody defects: everybody does their best","volume":"41","author":"Salinas","year":"2021","journal-title":"J Clin Immunol"},{"key":"2024080909361052900_CIT0025","doi-asserted-by":"crossref","first-page":"15606","DOI":"10.1038\/s41598-022-19537-2","article-title":"Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain","volume":"12","author":"Fern\u00e1ndez-Ciriza","year":"2022","journal-title":"Sci Rep"},{"key":"2024080909361052900_CIT0026","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s10875-023-01514-7","article-title":"Immune responses 6 months after mRNA-1273 COVID-19 vaccination and the effect of a third vaccination in patients with inborn errors of immunity","volume":"43","author":"van Leeuwen","year":"2023","journal-title":"J Clin Immunol"},{"key":"2024080909361052900_CIT0027","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current State of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"2024080909361052900_CIT0028","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1038\/s41586-023-06355-3","article-title":"A second update on mapping the human genetic architecture of COVID-19","volume":"621","author":"Kanai","year":"2023","journal-title":"Nature"},{"key":"2024080909361052900_CIT0029","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s10875-023-01510-x","article-title":"Inherited STAT1 deficiency in a child with BCG-osis and severe COVID-19 pneumonia","volume":"43","author":"Gu\u00e8ye","year":"2023","journal-title":"J Clin Immunol"},{"key":"2024080909361052900_CIT0030","doi-asserted-by":"crossref","first-page":"719115","DOI":"10.3389\/fimmu.2021.719115","article-title":"Genetic screening for TLR7 variants in young and previously healthy men with severe COVID-19","volume":"12","author":"Solanich","year":"2021","journal-title":"Front Immunol"},{"key":"2024080909361052900_CIT0031","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3390\/ijms23136979","article-title":"Major histocompatibility complex class I chain-related \u03b1 (MICA) STR polymorphisms in COVID-19 patients","volume":"23","author":"Guti\u00e9rrez-Bautista","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024080909361052900_CIT0032","doi-asserted-by":"crossref","first-page":"108790","DOI":"10.1016\/j.celrep.2021.108790","article-title":"Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2","volume":"34","author":"Gasser","year":"2021","journal-title":"Cell Rep"},{"key":"2024080909361052900_CIT0033","doi-asserted-by":"crossref","first-page":"14909","DOI":"10.1038\/s41598-022-19073-z","article-title":"Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies","volume":"12","author":"Takahashi","year":"2022","journal-title":"Sci Rep"},{"key":"2024080909361052900_CIT0034","doi-asserted-by":"crossref","first-page":"17404","DOI":"10.1038\/s41598-023-44484-x","article-title":"Neutralization against Omicron sublineages (BA. 2\/BA. 5\/BQ. 1.1\/XBB\/XBB. 1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with omicron","volume":"13","author":"Amano","year":"2023","journal-title":"Sci Rep"},{"key":"2024080909361052900_CIT0035","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1038\/s41467-023-41678-9","article-title":"Omicron variant neutralizing antibodies following BNT162b2 BA. 4\/5 versus mRNA-1273 BA. 1 bivalent vaccination in patients with end-stage kidney disease","volume":"14","author":"Yau","year":"2023","journal-title":"Nat Commun"},{"key":"2024080909361052900_CIT0036","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.it.2021.09.001","article-title":"Immune imprinting and SARS-CoV-2 vaccine design","volume":"42","author":"Wheatley","year":"2021","journal-title":"Trends Immunol"},{"key":"2024080909361052900_CIT0037","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.chom.2023.12.003","article-title":"Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA. 2.86 variant","volume":"32","author":"Nesamari","year":"2024","journal-title":"Cell Host Microbe"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae039\/57707501\/uxae039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/217\/3\/253\/58780769\/uxae039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/217\/3\/253\/58780769\/uxae039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T18:00:26Z","timestamp":1723226426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/217\/3\/253\/7661018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,8,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae039","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,2]]}}}